Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of HY209 Gel in Patients With Mild to Moderate Atopic Dermatitis(AD)

NCT06024499 is registered in ClinicalTrials.gov with Shaperon as lead sponsor.

NCT NCT06024499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06024499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of HY209 Gel in Patients With Mild to Moderate Atopic Dermatitis(AD)
Lead sponsor
Shaperon
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2024
Completion date
April 13, 2026
Enrollment
210 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic dermatitis eczema, atopic dermatitis of scalp